NCT07686367
Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Nov 23, 2026 to Jan 19, 2027
Notable Start date: Sep 11, 2026 to Nov 23, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 31 words
- Interventions: Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C (Biological), Biopsy Procedure (Procedure), Biospecimen Collection… to Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C (Biological), Biopsy Procedure (Procedure), Biospecimen Collection…
- Secondary endpoints: details revised at 3 of 4 entries
- Study description revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Overall response rate
Timeframe: Up to 8 cycles (Cycle length = 21 days)
Secondary (4)
Progression free survival (PFS)
Overall survival (OS)
Preferentially expressed antigen of melanoma (PRAME) expression
Changes in circulating tumor deoxyribonucleic acid (ctDNA)
Arms and interventions
Treatment (brenetafusp [IMC-F106C])Experimental
Patients receive brenetafusp (IMC-F106C) IV over 15-60 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the study as well as biopsy and blood sample collection on study.
Biologicals: Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C
Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging